Zentalis Pharmaceuticals (ZNTL)

• Market cap: $160M
• 1 day: -2.37%
• 5 days: -8.86%
• 1 month: 0%
• 3 months: 78.99%
• 6 months: 62.5%
• Year to date: 80.29%
• 1 year: 24.75%
• 5 years: -93.91%
• 10 years: -89.35%
• Sector: Healthcare
• Industry: Biotechnology

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 166